Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200567 | 0.93 | LMNA (0.44) | JAK3JAK1HCRTR1HCRTR2LMNA | |
| SCHEMBL25438879 | 0.89 | LMNA (0.48) | HCRTR1HCRTR2LMNAHTTMEN1 | |
| SCHEMBL31200724 | 0.86 | LMNA (0.41) | JAK3JAK1HCRTR1HCRTR2LMNA | |
| SCHEMBL31200661 | 0.84 | GPR119 (0.46) | JAK1HCRTR1HCRTR2HTTMEN1 | |
| SCHEMBL25417272 | 0.84 | GPR119 (0.46) | JAK1HCRTR1HCRTR2HTTMEN1 | |
| SCHEMBL31200755 | 0.81 | JAK3 (0.44) | JAK3JAK1HCRTR1HCRTR2TRPV1 | |
| SCHEMBL30427885 | 0.81 | HCRTR1 (0.41) | HCRTR1HCRTR2LMNAHTTMEN1 | |
| SCHEMBL25437423 | 0.80 | NLRP3 (0.50) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL31200506 | 0.80 | NLRP3 (0.50) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL31200531 | 0.80 | USP30 (0.42) | LMNAHTTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | JAK3 1770/4885JAK1 2226/4885HCRTR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.